StemCell Therapy

With America on lockdown the past two months, many people turned to the woods for safe isolation and social distancing. And now as sections of the country reopen and summer approaches, the outdoors will be filled with hikers, campers, hunters and fishermen. It will also be filled with ticks that may be carrying the bacterial infection that spreads Lyme disease to humans and pets.

Unlike a mosquito bite where people know immediately if they have been bitten, a tick bite may go undetected; and one of the challenges with Lyme disease is that symptoms may not appear for two to six weeks. That makes it critically important to take steps to avoid catching the disease and to know its warning signs so treatment can begin early when it is most effective.

"While not all deer ticks cause Lyme disease, it is still smart to avoid areas where deer ticks live, especially wooded, bushy areas with long grass," said Sean McCloy, M.D., a family medicine physician with an expertise in Lyme disease at the Integrative Health Center of Maine. "You can decrease your risk of getting Lyme disease with some simple precautions, such as wearing shoes, long pants tucked into your socks, a long-sleeved shirt, a hat and gloves. And after spending time in vulnerable areas you should always check your clothing, yourself, your children and your pets for ticks; and remove any that you find as soon as possible with tweezers. Only a minority of tick bites leads to Lyme disease; but the longer the tick remains attached to your skin, the greater your risk of getting the disease."

For those who are bitten by an infected tick, early warning signs include fever, headache, fatigue, joint pain, swollen lymph nodes, weakness in the limbs and a characteristic skin rash often in a bull's-eye pattern. If untreated, new symptoms could include neurological problems and, though less common, heart problems (such as an irregular heartbeat), eye inflammation, liver inflammation and severe fatigue.

"If you think you've been bitten and have signs and symptoms of Lyme diseaseparticularly if you live in an area where Lyme disease is prevalentit is critical to get tested as treatment is more effective if begun early," said Robert Dracker, M.D., chairman of the heart, lung and cancer committee for the Medical Society of New York and medical director of Summerwood Pediatrics and Infusacare Medical Services in New York. "Fortunately, new tests are available that are easy to administer and provide results faster than ever."

Leading the way in Lyme disease testing is the innovative Sofia 2 Lyme FIA test. This in-office test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctors office or local clinic, it is also the only test that can get results from a simple finger prick of blood. The test was developed by Quidel, a California-based diagnostic healthcare manufacturer and one of the nations leaders in developing rapid diagnostic health solutions.

"Given that the vast majority of patients tested are negative, getting results quickly will mean discernable peace of mind and remove a significant weight off a persons shoulders," said Dr. Dracker. "Not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative."

Patients seeking more information are encouraged to contact their private physician to find out more about the availability of this innovative new test in their area. More information on Quidel may be obtained at quidel.com.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Quidels products aid in the detection and diagnosis of many critical diseases and conditions including not only Lyme disease but, among others, influenza, respiratory syncytial virus, strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidels research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians offices and hospital and reference laboratories. For more information about Quidel, visit quidel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005149/en/

Contacts

Jim Yeager424-644-0225 (office)818-264-6812 (mobile)jim@breakwhitelight.com

See the article here:
Knowing Signs and Symptoms of Lyme Disease Is Critical for Early Detection and Treatment, Says Industry-Leading Quidel - Yahoo Finance

Calmaria means calm in Portuguese, and is the word chosen by Fabio Sasso to launch his first application. Sassos name may not sound too much to you, but its a designer who currently works for Google and he is the founder of Abduzeedo: a prestigious blog design that we have already talked about on other occasions.

In the midst of a global pandemic and seeing racial unrest increase in the United States, one could feel somewhat anxious. There are many breathing techniques to relax, and Calmaria invites us to try a well-known one.

Obviously, coming from the hand of Abduzeedo, design is one of its most striking points. A kind of minimalist sunset, with warm tones, will indicate the way in which we must breathe.

Although there are many websites and applications that use this method, the truth is that a nice and easy to follow interface It can help us establish a habit or that we feel like using it throughout the day.

Calm is based on the 4-7-8 technique, a method designed by Dr. Andrew Weil (director of Integrative Medicine at the University of Arizona and a popular character in the United States).

As the name suggests, this technique is made up of three steps different: inhale for four seconds, hold your breath for seven seconds and exhale for eight seconds.

It has a web app and an Android version (the iOS version will be soon)

We will not have to be counting time, since this app will indicate the missing seconds in each phase at all times. Currently it has a web app and an Android version, and they assure that soon the iOS version will arrive. Another positive point is that its completely free.

ShareAbduzeedo launches its first app: beautiful and minimalist design that helps us breathe and relax

Read more:
beautiful and minimalist design that helps us breathe and relax - Explica

Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure

NASHUA, N.H., June 01, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy, on June 4, 2020 at 7 pm ET/4 pm PT. Event registration is available via this link: https://register.gotowebinar.com/register/5960832272590383888.

The roundtable will feature leading specialists in breast cancer treatment, including the following experts*:

The COVID-19 pandemic has introduced unprecedented challenges to our health care system and specifically impacted cancer screenings and treatment in our country and worldwide. During these extraordinary times, it is imperative for clinicians to share best practices and adapt approaches to patient care. iCAD is honored to host virtual events such as this, which provide an educational forum for clinicians to enhance patient care during this global healthcare crisis and beyond, according to Stacey Stevens, President of iCAD. In the face of this pandemic, iCADs technology is now more relevant than ever. Intraoperative radiation therapy (IORT) with the Xoft Axxent Electronic Brachytherapy (eBx) System offers a viable solution that could potentially alleviate the burden to our health system, while enabling clinicians to administer high-quality care to patients who are candidates, while minimizing their potential exposure to the novel coronavirus.

Xoft breast IORT is a single-fraction therapy option that allows select early-stage breast cancer patients to replace weeks of daily radiation with one treatment, delivered at the time of surgery. This targeted treatment option offers a full course of radiation in just one day, which could contribute to a reduction in the healthcare system resources needed for breast cancer patients during the COVID-19 pandemic and reduce those patients risk of exposure to the novel coronavirus by minimizing the number of visits required to a hospital or medical facility.

In the recent months during the COVID-19 pandemic, hospital resources have become limited in many areas, and guidelines issued by a number of medical societies advise clinicians to determine how best to triage the care of cancer patients safely.1 Some breast cancer patients are choosing to delay parts of their treatment for safety concerns, according to Sadia Khan, DO, FACS, Assistant Clinical Professor of Surgery at Keck School of Medicine, USC, Director of Integrative Breast Oncology at Hoag Breast Program. In areas where there is still a high incidence of COVID-19, some patients with breast cancer may opt to choose IORT, which offers a one-dose radiation option for patients who meet the criteria. For those who are candidates, IORT gives patients an additional option to complete their radiation in a one-time dose, which decreases their exposure to the hospital.

Positive results from a long-term study involving Xoft breast IORT conducted at Hoag Memorial Hospital Presbyterian were published in the Annals of Surgical Oncology in 2019.2 Led by Melvin J. Silverstein, MD, Medical Director of the Hoag Breast Center, the prospective study, titled Intraoperative Radiation Therapy (IORT): A Series of 1000 Tumors, found breast cancer recurrence rates of patients who were treated with Xoft breast IORT were comparable to those seen in the cornerstone, randomized TARGIT-A and ELIOT trials, which evaluated IORT using different technology.

A number of breast cancer patients at our facility have had their treatment delayed due to the COVID-19 pandemic. This is concerning to physicians and patients alike, as some cases could potentially progress and it could result in a considerable backlog of patients who require urgent treatment with more advanced disease, according to Michael Howard, PhD, DABMP, RSO, Director of Oncology Services, Chief of Medical Physics, Sarah Cannon Cancer Institute, Parkridge Medical Center, HCA Healthcare. The concern for a second wave of COVID is very real, but IORT offers a way to help reduce this potential backlog.

Story continues

The reality is, IORT may be able to play a bigger role right now in the treatment of patients. In some cases, it may be ultimately more beneficial to offer IORT to avoid the backlog in treatment as a means of not overrunning hospitals and radiation centers once we are back up and running, added Barry Rosen, MD, FACS, Chief of Breast Surgery, Advocate Healthcare and Managing Partner, TME. IORT is one of those exceptional interventions that I believe satisfies the triple aim in treatment: it offers benefits to patients, providers and payers alike. For patients, it offers added convenience, with better cosmetic outcomes and fewer side effects; from a physician standpoint there is an inherent efficiency, as it enables them to condense one month of daily treatments to a single dose of targeted radiation. Lastly, for payers, the overall cost of treatment is reduced as the course of treatment may be reduced from weeks of daily fractions to one concentrated dose of radiation, administered at the time of surgery.

As clinicians, we are going to have to adapt to the COVID-19 situation as it evolves. At a certain point, delaying treatment for even early-stage breast cancer is going to come with risk. In many cases, the decision really should be made to go forward with cancer treatment; IORT offers a treatment option that may allow more women to get the treatment they need during this time, according to Charles Wesley Hodge, MD, Radiation Oncologist, Florida Hospital Celebration Health/AdventHealth. We are facing an unprecedented challenge in healthcare, and as clinicians we need to come together and adjust to these new realities. For those of us who practice in the oncology space, it is particularly challenging because we are dealing with a potentially life-threatening illness that requires appropriate management. Now is the time for clinicians to work together, to adjust to our new reality, and to come up with an approach that will do the greatest good for our patients.

This virtual roundtable event is a part of larger series of webinars hosted by iCAD in recent weeks, featuring leading experts in breast cancer detection and treatment. This series has examined various aspects of breast cancer care in the era of COVID-19, including risk adaptive tools and pragmatic solutions for both screening and treatment. To view the schedule, register for an upcoming free event, or view a prior event on-demand, visit https://www.icadmed.com/educational-webinars.html.

*Panelists have been compensated with an honoraria/speaking fee, but are encouraged to provide their own expert opinions and viewpoints. Dr. Patel is a member of iCADs Board of Directors.

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

ProFound AI is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.1

The Xoft System is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.

For more information, visitwww.icadmed.com and http://www.xoftinc.com.

Forward-Looking Statements

Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Companys technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Companys ability to achieve business and strategic objectives, the ability of IORT to alleviate the burden to our health system and minimize a patients potential exposure to Covid-19, to be more beneficial for patients that traditional therapy or to be accepted by patients or clinicians, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Companys filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website athttp://www.icadmed.comand on the SECs website athttp://www.sec.gov.

Contacts:Media inquiries:Jessica Burns, iCAD+1-201-423-4492jburns@icadmed.com

Investor Relations:Jeremy Feffer, LifeSci Advisors+1-212-915-2568jeremy@lifesciadvisors.com

Read more:
iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19 - Yahoo Finance

At some point, youve probably been told totake a deep breathin a moment of anxiety. As it turns out, theres more to the clich than you might think. We spoke to experts about 4-7-8 breathing, a technique that, in a matter of seconds, can ease your negative response to stress. Inspired by yoga, 4-7-8 breathingisnt just a psychological tool: It can actually change the speed at which your heart beats and promote the effective pumping of blood to various organs and muscles. Heres how (and why) to do it.

Its a breathing pattern based on pranayama, which is the part of yoga that deals with breath control. 4-7-8 is relaxing because it extends the exhale portion of the breathing, said Dr. Victoria Maizes, the executive director of the Andrew Weil Center for Integrative Medicine at the University of Arizona. Extending the exhale has a quieting effect on the body by interacting with the parasympathetic nervous system (essentially the flip side of the fight-or-flight stress response).

Its free,its simple, and you can choose to use it any time youre feeling stressed.

Sit upright with your chest open and put the tip of your tongue at the roof of your mouth. Theres a little ridge behind your upper front teeth where your tongue will stay for the entire exercise (the placement of which will cause a whoosh sound when you exhale). Inhale through your nose to the count of four, hold your breath for seven counts, and exhale slowly through your mouth for eight counts (you can purse your lips while exhaling if that feels more comfortable for you).

This is one breath, so do this three more times for a total of four breaths. If its helpful, you can count on your fingers to track how many cycles youve done. You have to exhale slowly or else youll run out of air pretty fast, since your exhale is now twice as long as your inhale, says Maizes. The ratio is whats important not the exact time you spend on each phase so you can speed the whole thing up or slow it down as long as you keep the 4-7-8 count intact.

I think its hard to learn anything new when youre really anxious, but in particular, I think its hard to learn to relax, says Maizes, which is why she suggests making 4-7-8 a practice by doing it twice a day, every day. You can do it more than twice a day do it 20 times a day if you want but you should only do the 4-7-8 breath four times in a row at a time. Once you get really good at it after practicing it for about a month or longer the typical recommendation is to bump it up from four to eight times in a row, but no more. (Its not exactly clear why this restriction exists, but Maizes theorises that its because you can blow off more carbon dioxide while slowly exhaling, and doing too much of that could make you lightheaded or uncomfortable.)

Because youre doing no more than four cycles (or, eventually, eight) at a time, the exercise will only take seconds. It is physiologically impossible to be stressed and relaxed at the same time, Maizes said. Practicing 4-7-8 breathing makes your nervous system smarter, so then if youre anxious, your body goes, Oh yeah, I know how to relax. Ive been practicing this for weeks. Sometimes, Maizes adds,if youre feeling really anxious, you might have difficulty both taking a deep breath and holding your breath. Thats why its helpful to familiarise yourself with the practice throughout the day, particularly in moments when you are not feeling stressed. The more you practice it and get better at it, the more helpful it will be for you when youre feeling a lot of anxiety, says Dr. Sarah Kate McGowan, assistant clinical professor in the department of psychiatry and behavioural sciences at the David Geffen School of Medicine at UCLA. Thats not to say that you shouldnt try 4-7-8 in the moment if youve never done it before it will likely still be helpful but ina highly anxious moment, its easier to draw on something youve done before.

Its free,its simple, and you can choose to use it any time youre feeling stressed. Part of anxiety is loss of control, says McGowan. With something like 4-7-8, you dont need to rely on anyone but yourself. Dont underestimate the self-efficacy aspect of this practice.

But there are physiological components at play, too. This sort of breathing helps regulate the bodys stress response the fight or flight reaction that helps us survive life-threatening situations. In stressful circumstances, your breath increases in order to get extra oxygen to your lungs and your brain helpful, should you actually have to fight or take flight. But in a lot of modern day stressors, there isnt a physical threatcreating that anxiety.So what were doing with breathing exercises is trying to slow down our bodys sympathetic response, McGowan said.

The bodys stress response isnt inherently a bad thing. Even fruit flies have a stress response, said Dr. Esther Sternberg, research director at the Andrew Weil Center for Integrative Medicine. You cannot live without it. The goal is not to get rid of the stress response thats not possible. The question is how you turn that negative stress into good stress and make it work for you.

And the way to do that is by engaging whats called the relaxation response. This response isactivated by the vagus nerve, which connects the spinal cord to the internal organs of the body. One way to quickly engage the vagus nerve in other words, to quickly engage the relaxation response is through deep breathing. Its like putting your foot on the brake and putting the brake on the stress response, Sternberg says.

Breathing deeply changes the speed at which your heart beats.

Breathing deeply changes the speed at which your heart beats. If you look at one minute of heart rate, youll see that your heart doesnt beat exactly evenly. This is whats called heart rate variability, which is the variation in the spaces between the beats. Thats because the vagus nerve is directly connected to the part of the heart that controls heart rate, the rhythm center, says Sternberg. When you inhale the heart rate increases, and when you exhale, it decreases. As you breathe deeply, it changes the speed at which the heart beats, so you get more variability. The greater the heart rate variability, the more effective the pumping of the blood to all your different organs and muscles.

Just as there are brain pathways engaged with negative experiences of stress, Sternberg says positive experiences such as deep breathing, walking in nature, and even prayer engage other brain pathways that are rich in endorphins and feel-good molecules. In addition to making you feel good, they contribute to putting that break on the stress response, Sternberg says. Remember,if youre feeling anxious, your body is telling you something. she says. As soon as you change course, you shift from feeling stressed to feeling exhilarated the difference between the two feelings is whether or not youre in control.

This article originally appeared on Science of Us 2020 All Rights Reserved. Distributed by Tribune Content

Link:
How to breathe using the 4-7-8 technique if you're feeling anxious - SBS

In the times when India is grappling due to the COVID-19 situation, swarms of locust attacking various parts of the country is another formidable challege the country has to tackle. According to the Agriculture Ministry, nearly 15 districts in Rajasthan and Madhya Pradesh have experienced locust attacks which are still active.

The Ministry of Agriculture and Farmers Welfare on Wednesday informed that locust control operations have been stepped up in affected states to combat the menace.

"Amidst a wave of locust swarms sweeping across western & northwestern India, Department of Agriculture & Farmers' Welfare has stepped up locust control operations in affected states of Rajasthan, Punjab, Gujarat & Madhya Pradesh," said the Agriculture Ministry in a press release.

The ministry further added: "As of today, there are active swarms of immature locust in Barmer, Jodhpur, Nagaur, Bikaner, Ganganagar, Hanumangarh, Sikar, Jaipur Districts in Rajasthan and Satna, Gwalior, Seedhi, Rajgarh, Baitul, Devas, Agar Malwa district of Madhya Pradesh."

The ministry further informed that till 26 May, control operations against locusts done in 47,308-hectare area at 303 places in Rajasthan, Punjab, Gujarat, and Madhya Pradesh by Locust Circle Offices (LCO) in coordination with District Administration and State Agriculture Department.

View original post here:
Swarms of locust still active in 15 districts of Rajasthan, Madhya Pradesh - Free Press Journal

Quick and Cheap: RT-Lamp COVID-19 tests to cost up to Rs 200, give results in less than an hour, says CSIR  |  Photo Credit: iStock Images

New Delhi [India], May 27 (ANI): The Council for Scientific and Industrial Research (CSIR) has signed an MoU with Reliance to develop a new RT-LAMP COVID-19 diagnostic kit, which is cheap and gives a quick result, said Director-General Dr Shekhar C Mande on Wednesday.

COVID-19 RT-LAMP (Reverse Transcriptase-Loop Mediated Isothermal Amplification) test is a nucleic acid-based test carried out from nasal or throat swab samples from the patients. The test has been developed and successfully demonstrated using synthetic templates.

Talking about the test, Dr Mande said that "RT-LAMP test is cheap because you don't need to have instrument cost. It's also quite quick. You can actually take it into different areas. You can very quickly take it into the rural area."

The CSIR on Tuesday had announced that the Institute of Integrative Medicine in Jammu has tied up with Reliance Industries Ltd to develop and scale-up a new RT-LAMP based COVID-19 diagnostic kit.

Dr Mande said that the new testing kit "could cost between Rs 100 and Rs 200. It will take less than an hour for a test to do. Within one hour, we can get the result."

Talking about the difference between Feluda test and RT-LAMP kit, Dr Mande said: "Technological basis of Feluda kit and RT-LAMP kit is different. Faluda is based on technique call crisper cash, while RT-LAMP is based on RT-PCR. There is isothermal PCR. So, the technology of both kits is different."

"RT PCR requires a specialised machine. The first step is a reverse transcription that is common to both RT-PCR as well as RT-LAMP. The second step is once DNA is made from RNA, the PCR quantitative to PCR machine does three cycles of temperature," added he.

The CSIR-DG said further said: "In this condition, you do something at 92 degrees; you do something at 55 degrees; you do something at 73 degrees, and you keep cycling between these three temperatures about 25 and 30 times, and in each cycle the number of DNA molecules doubles and you measure. That is in the fluorescent level. So that is a base of RT-PCR."

"But RT-PCR required this machine the fluorescent level is costly and it takes time. On the other hand, the RT-LAMP test is using only four to six primers for the amplification of DNA. It uses four and six primers and you do the amplification of DNA. First of all, it is common for converting RNA into DNA. When in the second step, you use only a single temperature something like 60-degree Celsius," he added.

Dr Mande informed that the Institute of Integrative Medicine in Jammu and Reliance Industries Ltd have agreed that they will scale up the production of the test kit.

Continue reading here:
Quick and Cheap: RT-Lamp COVID-19 tests to cost up to Rs 200, give results in less than an hour, says CSIR - Times Now

The coronavirus is pushing telemedicine to the forefront of healthcare, but not all ETFs are adequately levered to this theme. The Principal Healthcare Innovators Index ETF (Nasdaq: BTEC), does however, feature some telemedicine exposure.

BTECtracks the Nasdaq U.S. Healthcare Innovators Index, which is designed to provide exposure to early-stage small-capitalization healthcare companies. These are primarily biotechnology and life science, which have the potential to create cures for cancer, develop new medical technologies, or spearhead other medical advances.

High-flying Teledoc Health (NASDAQ: TDOC) is a top 10 holding in BTEC and another example of the ETFs leverage to themes emerging from the coronavirus.

BTEC, which turns four years old in August, seeks to tap into the increasing demand for healthcare solutions as demographic trends have driven healthcare spending to more than double in the last 20 years, according to Principal.

With telemedicine still in its nascent stages, theres ample runway for growth and that could underscore the already compelling long-term thesis for BTEC.

With Americans wary of hospitals and clinics as potential vectors of infectious disease, more are starting to appreciate telemedicine and communicating with their health-care providers online, according to CNBC.

Since the coronavirus outbreak, health care technology has come to the fore with various innovations to combat the virus. This can only help fuel health care technology exchange-traded funds (ETFs) moving forward from preventative medicine to treatment.

Disruptive technology is not relegated to certain sectors as it will permeate into all industries in some form or fashion. For example, augmented reality is technology comprised of digital images superimposed over the real world, and its use is primed to drive industry growthindustries like real estate and manufacturing are already putting the technology to use in a variety of ways.

Importantly, BTEC is a passive fund with an active index structure, one that removes large-cap and less liquid companies as well as those with inconsistent or negative earnings trends. Conversely, BTEC focuses on research and development-focused firms that have the potential to deliver legitimate disruption.

Online healthcare services and telemedicine will continue to become more prevalent and essential. We see the potential for continued greater use of digital technologies to benefit patients and result in fewer visits to the clinic, said Jefferies strategist Simon Powell in a recent note to clients.

For more on multi-factor strategies, visit our Multi-Factor Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

See the original post here:
Telemedicine Is One Contributor to This Healthcare ETF's Compelling Story - ETF Trends

BANGOR, Maine (WABI) - Housing advocates from several organizations held a live online event Monday to highlight the challenges many renters face right now.

Several Mainers shared their stories of having no money for rent or being unable to find safe housing.

The pandemic has thrown a spotlight on some of the ways vulnerable populations have been under-served.

They called for a moratorium on evictions and foreclosures, a cancellation of rent and housing for the homeless.

They also want the Maine Housing Authority emergency rent relief fund expanded.

Crystal Cron, President of Prsente! Maine, led the discussion.

The public health of our community depends on the health of the entire public. We need to protect all of us and ensure that the basic needs of our community are met during this public health crisis and always. Housing is the preventative medicine we need to keep our community safe in the next crisis. Lets make sure we learn from this crisis and get people secure housing right now.

You can find a link to the full recorded livestream below.

Link:
Housing advocates call for expanded aid to those struggling to pay rent or find housing - WABI

STEAMBOAT SPRINGS As the accuracy of COVID-19 antibody tests improve and become more readily available, questions linger about the information those tests can provide.

Of the 1,000 tests the Steamboat Emergency Center obtained, theyve only administered several hundred at this point, according to Dr. Jesse Sandhu. As a result of the low testing number, he said its too soon to get a sense of how many Routt County residents have been exposed to the virus.

However, Sandhu said theyve been surprised thus far at how many people are testing positive for the antibodies.

Steamboat Emergency Center is also using multiple levels of verification, including a PCR diagnostic test as well as sending some of the antibody tests to a lab for the more sensitive ELISA test.

Support Local JournalismDonate

The point is the antibodies are there, Sandhu said. We are getting a surprisingly decent amount of positives.

Most of the people going in for the antibody tests believe they were exposed to COVID-19 around February or March, Sandhu said, before testing was available to anyone other than the most critically ill.

At a local level, Sandhu said one of the most valuable pieces of information that can come from the centers data subset will be in tracking people with antibodies to see if they get reinfected with the virus.

Only then can doctors and scientists better understand what level if any of immunity people have who have previously been exposed to COVID-19.

As of last week, UCHealth is also offering antibody test and diagnostic testing to anyone who wants it in Colorado.

Many people have been interested in getting antibody tested, because they want to know if they have been exposed to COVID-19, or they want to know if they are possibly immune to COVID-19, said UCHealth Chief Innovation Officer Dr. Richard Zane in a news release. Unfortunately, for now, the only thing we can tell you is that, if you have antibodies, you have been exposed to COVID-19. We cannot tell you, yet, whether you are immune to it.

While there has been a lot of concern about the accuracy of antibody tests, the tests being used by the Steamboat Emergency Center and UCHealth Yampa Valley Medical Center are authorized by the Food and Drug Administration.

There are only a few FDA-authorized tests currently on the market.

The antibody tests that UCHealth now provides have been evaluated by the FDA and far exceed the agencys requirements for accuracy and specificity, according to a UCHealth news release. These are among the few antibody tests authorized by the FDA, and they are among the most accurate being offered in the nation. The test UCHealth is offering is greater than 98% specific, meaning that there are fewer than one in 1,000 errors.

The test being used at the Steamboat Emergency Center has a specificity of 96%.

There are many commercial tests available and being utilized at other medical facilities, Sandhu said. Many of these test are not accurate and do not have FDA authorization. Always ask the brand of the test being used and cross reference it on the FDA site to make sure it is truly authorized.

While most insurance plans do cover both the antibody and diagnostic tests, health care providers are recommending patients check with their individual plans.

In terms of out-of-pocket costs, Steamboat Emergency Center is offering the antibody test for $199. Yampa Valley Medical Center offers theirs for $100.

We have very high confidence in the antibody test UCHealth is now able to offer, said Dr. Laura Sehnert, the hospitals chief medical officer. However, we still have a lot to learn about what it truly means to have COVID-19 antibodies how long theyll last, if theyll prevent re-infection, etc.

The presence of COVID-19 antibodies does not mean you can forget everything weve done over the last few months, Sehnert explained. Our community has done a great job social distancing, wearing masks and performing hand hygiene. As Steamboat Springs begins to welcome back second homeowners and visitors, it remains of the utmost importance for all of us to continue to practicing these behaviors.

Sandhu notes that while people are hoping the summer season slows the virus down, that is far from a certainty at this point. He also observed that people may concentrate travel plans to places like Routt County, knowing there is low disease prevalence, and it is easier to social distance.

But he is excited about getting more antibody data going forward, especially as the early results provide evidence that more people had it then realized. Some of the people who tested positive for antibodies are reaching out to others they had close contact with around the time they were sick, Sandhu said, and encouraging them to also get an antibody test.

In terms of diagnostic testing, the Routt County Department of Public Health will continue to offer drive-thru testing through June and July. And as supplies increase, they continue to opening up testing to more people, including asymptomatic volunteers.

Kari Ladrow, public health director for Routt County, also emphasized the importance of contact tracing going forward.

Contact tracing is one of the cornerstones of preventative medicine and public health and is particularly crucial in the current pandemic by identifying individuals who have been exposed quickly and isolating, quarantining and testing them, Ladrow said in a news release. Community participation in the process of contact tracing is critical for virus suppression and continued economic and community recovery.

The disease mitigation efforts our county has undertaken appear to have been very effective, Routt County Public Health Medical Officer Brian Harrington said in a May 27 news release. The opening of restaurants and short-term lodging represent factors that could increase the presence and transmission of COVID 19 in our community. I emphasize that COVID-19 remains in our community.

Just this weekend, we had a resident of Craig test positive, Harrington continued. That resident had been in our county while infected with the COVID-19 infection. It is important that people in Routt County continue to practice social distancing, wear face masks in public and stay at home if sick with COVID-19 symptoms until they have contacted their primary care provider or gotten a negative COVID-19 test.

To reach Kari Dequine Harden, call 970-871-4205, email kharden@SteamboatPilot.com or follow her on Twitter @kariharden.

Continue reading here:
COVID-19 antibody and diagnostic testing continues to increase locally - Steamboat Pilot and Today

As the temperatures continue to rise and the days grow longer, many rural Minnesotans start spending more time outdoors. Campers, hikers, hunters or those enjoying a bit of recreation time in a park or any wooded area are likely familiar with a small, eight legged creature that could cause a lot of trouble: ticks.

Morrison County itself is noted as a high-risk area for people contracting Lyme disease, and according to David Neitzel, an infectious disease epidemiology researcher with the Minnesota Department of Health, central Minnesota is unfortunately a hotbed for ticks in general.

The state is home to 12 species of ticks, but the ticks most interested in human blood, and most dangerous to humans, Neitzel said, are the blacklegged tick, formerly called the deer tick and the American dog tick, a standard wood tick.

Although dog ticks are usually just an unwelcome pest, they can carry diseases that transmit to humans such as the Rocky Mountain Spotted Fever and Tularemia, although it is rare. This tick is widespread across the state and can inhabit wooded and prairie type areas, they are typically brown with cream colored markings, Neitzel said.

In central Minnesota in general the blacklegged tick numbers seem to be much higher than in other parts, he said.

The blacklegged tick is just 1/2 to 2/3 the size of its wood tick counterpart, and carries Lyme disease, the most common tick-borne disease.

Blacklegged ticks prefer woods and brushy habitat. If youre not walking around in the woods, youre not likely to come into contact with these ticks and the diseases that they transmit, he said.

Blacklegged ticks are not found in open areas as they are susceptible to dry weather and can die just by drying out, which is why they prefer the comfort of the damp leaves on the forest floor.

If we have some nice humid weather some ticks come out and they are ready to feed unfortunately, Neitzel said.

A difference in biology is also why a common wood tick doesnt spread Lyme disease. Neitzel said they can contract it when they are in early stages of life, but as they grow, the disease bacteria cant sustain itself in the body of a wood tick, however a blacklegged tick makes a perfect host.

Lyme disease and anaplasmosis, all those disease agents live in small animals like white footed mice, chipmunks and other common small mammals that we find across Minnesota. The ticks get infected with those disease agents when they feed on those small mammals, Neitzel said.

Ticks only feed once in each life stage, he said, so after hatching from an egg the larvae will find a small mammal to feed on, then as a nymph and an adult they may attach to a larger host like a white tail deer or a human, possibly spreading a disease. Adult female ticks need their largest meal at that stage so they can lay thousands of eggs and start the cycle over.

Tick season starts as soon as the snow melts and adult sightings will fade out by July, Neitzel said. Then a second wave of adults will come out during the fall, another time to be cautious in the woods.

More important though is the nymph stage, that intermediate stage. They come out from mid-May to mid-July theyre about a millimeter in length, pure black/brown color really hard to see unless youre looking closely for them. A lot of people never really know they are bitten by a tick and thats the riskiest life stage because theyre so hard to see, he said.

Because of their small size, Neitzel said he likes to tell people to take even more precaution when they stop seeing adult ticks and think the season is over. Since ticks are cold blooded, they move faster in warm weather and are able to crawl from an ankle to the top of a head in maybe 20 minutes, Neitzel said. However a tick can be found anywhere constricted and warm such as an armpit, back of the knee or near the belt-line.

A tick can be present on a host for up to five days, Neitzel said, and if someone finds an engorged tick on themselves, its likely there was time to transmit whatever disease it was carrying.

For Lyme disease a tick needs to be attached for one to two days before it transits the bacteria. So the quicker you check yourself for ticks and the quicker you can get them off of you, the better, he said.

Luckily, making a point to search for ticks after every trip to the woods can drastically decrease the chance of contracting Lyme disease. Since his position requires him to attract ticks, Neitzel doesnt use repellent, and has relied on the search and remove method for years.

A shower will unfortunately not kill a wood tick, Neitzel said. Ticks breathe through holes on the side of their body and need very little oxygen, so if theyre submerged, they simply close the holes and can hunker down for hours if needed.

So, if a person isnt looking to attract ticks, they may want to take some precautions.

Some basic recommendations are to wear long light pants and pull long socks over the top of them to spot ticks quickly, then Neitzel recommends a repellent with Deet or Permethrin.

A lot of people that live in central Minnesota say I live out in the woods. I cant put on repellent every time I go outside, thats just not practical. We agree that itd be hard to do all the time, but Permethrin-based repellents are really good in that you can take the pants that you wear when you do yard work and you can treat those pants with Permethrin and the repellent lasts for several weeks even through multiple washings, he said.

Neitzel also said assuredly that Permethrin, also a treatment for head lice, has a very low toxicity to humans and does not slough after its dry, so children and pets exposed wont be affected.

About 40% of adult blacklegged ticks carry Lyme disease and about 20% of nymph ticks carry the disease, but again because of their size more people are infected with Lyme disease during nymph peak season, Neitzel said.

If someone has been in a wooded area in the past month and develops any unexplained rash or rashes with fever, muscle aches, fatigue or similar symptoms, Neitzel recommends a trip to the doctor. The sooner a person knows the better, he said, so if a tick is found obviously remove it and watch the bite location. The saliva from the tick can be irritating so a little redness may occur but if it worsens or turns into that unmistakable bullseye, its time to go in.

Only 63% of Lyme disease cases showed presentation of bullseye according to MDH. In 2018, 950 confirmed Lyme disease cases were reported in Minnesota with an additional 591 probable cases that did not meet clinical criteria but showed laboratory evidence of infection.

The number of cases has been on a steady incline showing a median range of 913 cases from 2000 to 2008, increasing to 1,203 cases from 2009 to 2017.

Each year 400 to 600 cases of anaplasmosis, another disease transmitted by a blacklegged tick, are reported by MDH, and about a quarter of cases are hospitalized each year. Other more rare diseases spread by blacklegged ticks include: babesiosis, Powassan virus disease and ehrlichiosis.

You dont have to go very far to find a tick infected with one of these disease agents and quite often ticks will be carrying more than one, Neitzel said.

Often when people go out into nature, they bring along their dogs, who can also contract Lyme disease. Dr. Amanda Craft at Animal Haven Veterinary Clinic in Little Falls said they talk to clients every day about ticks, prevention and treatment options.

Just within the last five years, Craft said there has been a lot of advancement in preventative medicine for dogs. Most clinics offer topical or oral treatment and some can last up to 12 weeks.

The products you find through a veterinarian are much more effective, are better studied and they are a lot safer than over the counter products, she said.

A topical treatment works by repelling ticks and an oral product will kill the ticks once they bite the dog. There is also a preventative vaccine for Lyme disease, so Craft said if all precautions are taken, risk to a dog is pretty low.

Preventing ticks from attaching to dogs is also important as they can contract anaplasmosis.

A lot of times when I tell people their dog has Lyme disease or anaplasmosis theyll say they were familiar with it because theyve had it which I find really interesting. It just shows how prevalent it is, said Craft.

Symptoms of Lyme disease infection for dogs include: fever, limping, poor appetite, soreness or not seeming like themselves. The diseases are so prevalent that Craft tests for them each year when she runs the annual heartworm disease test.

The ones that come in that are really ill that we see and diagnose and treat are ones that have no protection sometimes if theyre covered by a vaccine they are seeing less symptoms, she said.

We see a lot less disease in dogs that are treated with preventative measures that people are aware of and they dont want their dogs to get sick, she said.

A dog with untreated Lyme disease can go into kidney failure, Craft said, so paying attention to pets and taking precautions is the best way to prevent them from becoming very ill. The diseases can be treated with a simple antibiotic but catching it early is key.

Animals are so good at hiding illness that sometimes theyre sick for a while and get to the point where treatment is not an option, she said.

As for cats or rabbits, Craft said there is a topical preventative, but there isnt a Lyme disease vaccine. She said those animals are more likely to become anemic from ticks than they are to contract a disease.

For all pets, the search and remove method along with any preventative treatments, is the best way to prevent tick-borne diseases.

View original post here:
Outdoor enthusiasts reminded that tick season is in full swing - ECM Publishers

A medicine against the coronavirus may be ready within the coming six months, professor of cell biology Frank Grosveld of Erasmus University, said to NPO Radio 1. Grosveld and several other scientists discovered the first coronavirus antibodies in March, sparking hopes for a medicine.

Over the past weeks, much progress was made in testing the medicine on living beings, Grosveld said. "The medicine will be there in five, six months." An American company will be developing the medicine, but he could not say which company exactly.

Grosveld is hopeful that the impact of this medicine will be enormous. "This antibody responds to SARS1, it also works on the current coronavirus, which is also known as SARS2. If there is a SARS3, it is likely to respond well to it," he said. "You can use it as a medicine if you are already infected, and as a preventative for high-risk groups."

According to the professor, the Dutch government pushed several hundred thousand euros into this research.

Read more from the original source:
Coronavirus medicine ready within 6 months, antibody discoverer says - NL Times

Orlando, FL, June 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- eCare21 is pleased to announce that Dr. Bob Arnot, MD will join the company as Chief Medical Officer.Dr. Bob is a best-selling author, Emmynomineeand Dupont award-winning correspondent,producer, writer and recently joined the team atCOVID-19 Urgent Resource Video Education (CURVE)withMassachusetts General Hospital.

Dr. Arnot is also focusing on Machine Learning solutions with his broad background in systems architecture and user interface design. He has strong media and communication skills, is a Doctor of Medicine (MD) and has experience working with Google, Apple, NBC News, MSNBC, and HIMSS. Dr Bobs second focus is food technology with his deep background in analytical chemistry and human trials.

In addition, eCare21 is pleased to announce the engagement of THE CREATIVE MANAGEMENT AGENCY: Creative Management Partners LLC, and its CEO, Alan Morell, as the companys Senior Advisor with the goal of building the eCare21 brand within the rapidly expanding Senior Care and Virtual Care markets. Mr. Morell has 30 years of global experience in the successful development and management of talent, literary, TV and film packaging, commercial rights, corporate consulting, media positioning, sponsorship of live events and intellectual property (IP) rights. Mr. Morell is one of only a few in the sports, entertainment and arts industries who has represented and managed clients that have won the prestigious awards: Grammy; Tony; Oscar; Emmy, ESPY and Victors.

Vadim Cherdak, PhD, founder and CEO of eCare21, said, We are thrilled at the opportunity to work with Dr. Bob, one of the most recognized TV and media medical ambassadors and with his Uber-Agent, Alan Morell, who has made so many major books, movies, and TV programs happen. Mr. Morell manages more doctors than any agency in the world and we are excited to have his #1 doctor, Dr. Bob, join our team. We are looking forward to bringing Telehealth and advanced health care solutions to the home of every senior in the US and around the world.

When I was introduced to eCare21 by my longtime valued client, Dr. Bob Arnot, and my client Matt Weisensee, it was clear the team at eCare21 had built something very special, said Alan Morell, and preventative care technology would become essential, especially in these COVID-19 new normal times. I quickly realized we would need to leverage the reach of Broadcast Media to gain the attention of the majority of seniors who suffer from chronic illnesses. eCare21s patient-centric Virtual Care platform provides an easy-to-use, comprehensive turn-key solution that includes Telehealth and remote monitoring combined with patient engagement services to help avert potentially adverse health issues. In addition, after vetting Founder/CEO, Vadim Cherdak, and President/COO, Pete Stevenson, I found eCare21 Senior Management, with their cutting-edge Virtual Care solution, to have superior skillsets and expertise with high integrity who can implement their mission and be Wall Street friendly. I am honored to work with them, and I know Dr. Bob is as well.

About eCare21

eCare21 (eCare21.com) is a patient-centric Virtual Care Platformthat combines Telehealth, Remote Patient Monitoring and Chronic Care Management into unified SaaS solution for post-acute care for seniors. eCare21 is the first end-to-end solution for Virtual Care that creates a seamless workflow for delivering healthcare in the home to improve patient outcomes. eCare21 translates the remote patient encounters into billable events and generates a clean, compliant bill aligned with CMS policy. The eCare21 mobile Apps have been recognized as one of the best Apps for caregiving three years in row. For more details on the eCare21 Virtual Care Solution Powered by Dell Technologies: Clickherefor a short video.

Vadim Cherdak732-586-6842vcherdak@ecare21.com

Continued here:
Highly Respected Telemedicine Expert, Dr. Bob Arnot, Joins eCare21 Team Along With Alan Morell, Creative Management Partners, as Senior Advisor -...

The market is primarily driven by increasing number of cancer patients suffering from many different types of cancer. In addition, stem cell therapy is a painless and incision less treatment procedure is likely to boost the market growth. However, lack of suitable and donor matching sample might restrict the market growth.

Report:www.orianresearch.com/requestle/1040620

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Top Key Companies Analyzed inGlobal Cancer Stem Cell Therapy Market are Thermo Fisher Scientific, Merck Kgaa, Bionomics, Lonza, Stemline Therapeutics, Miltenyi Biotec, Promocell, Macrogenics, Oncomed Pharmaceuticals and Irvine Scientific

Key Benefit of This Report:

Global Cancer Stem Cell Therapy Industry 2019 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Report:www.orianresearch.com/040620

Target Audience:

Research Methodology:

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration.

Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:

Report:www.orianresearch.com/checkout/1040620

Major Points Covered in Table of Contents:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Global Cancer Stem Cell Therapy Market Overview

5 Global Cancer Stem Cell Therapy Market, by Product Type

6 Global Cancer Stem Cell Therapy Market, by Application

7 Global Cancer Stem Cell Therapy Market by Region

8 Competitive Landscape

9 Company Profiles

10 Key Insights

Customization Service of the Report:Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:Ruwin MendezVice President Global Sales & Partner RelationsOrian Research ConsultantsUS: +1 (832) 380-8827 | UK: +44 0161-818-8027Email: [emailprotected]Website: http://www.orianresearch.com/

Link:
COVID-19 Impact on Global Cancer Stem Cell Therapy Market 2020: Industry Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players...

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. It informs readers about key trends and opportunities in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

Key companies operating in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market include , Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1492429/global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment By Type:

, Platelet Rich Plasma Injections, Stem Cell Therapy Market

Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Segment By Application:

, Dermatology Clinics, Hospitals

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

Key companies operating in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market include , Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1492429/global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue1.4 Market Analysis by Type 1.4.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Platelet Rich Plasma Injections 1.4.3 Stem Cell Therapy1.5 Market by Application 1.5.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Share by Application: 2020 VS 2026 1.5.2 Dermatology Clinics 1.5.3 Hospitals 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Perspective (2015-2026)2.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Growth Trends by Regions 2.2.1 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Historic Market Share by Regions (2015-2020) 2.2.3 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Growth Strategy 2.3.6 Primary Interviews with Key Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players by Market Size 3.1.1 Global Top Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Players by Revenue (2015-2020) 3.1.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue Market Share by Players (2015-2020) 3.1.3 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Concentration Ratio 3.2.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Revenue in 20193.3 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players Head office and Area Served3.4 Key Players Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Product Solution and Service3.5 Date of Enter into Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Historic Market Size by Type (2015-2020)4.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Forecasted Market Size by Type (2021-2026) 5 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Application (2015-2026)5.1 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020)5.2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)6.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in North America (2019-2020)6.3 North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)6.4 North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 7 Europe7.1 Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)7.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Europe (2019-2020)7.3 Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)7.4 Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 8 China8.1 China Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)8.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in China (2019-2020)8.3 China Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)8.4 China Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 9 Japan9.1 Japan Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)9.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Japan (2019-2020)9.3 Japan Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)9.4 Japan Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)10.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)10.4 Southeast Asia Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 11 India11.1 India Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)11.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in India (2019-2020)11.3 India Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)11.4 India Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size (2015-2020)12.2 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Key Players in Central & South America (2019-2020)12.3 Central & South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Type (2015-2020)12.4 Central & South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size by Application (2015-2020) 13Key Players Profiles13.1 Orange County Hair Restoration Center 13.1.1 Orange County Hair Restoration Center Company Details 13.1.2 Orange County Hair Restoration Center Business Overview and Its Total Revenue 13.1.3 Orange County Hair Restoration Center Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.1.4 Orange County Hair Restoration Center Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020)) 13.1.5 Orange County Hair Restoration Center Recent Development13.2 Hair Sciences Center of Colorado 13.2.1 Hair Sciences Center of Colorado Company Details 13.2.2 Hair Sciences Center of Colorado Business Overview and Its Total Revenue 13.2.3 Hair Sciences Center of Colorado Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.2.4 Hair Sciences Center of Colorado Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.2.5 Hair Sciences Center of Colorado Recent Development13.3 Anderson Center for Hair 13.3.1 Anderson Center for Hair Company Details 13.3.2 Anderson Center for Hair Business Overview and Its Total Revenue 13.3.3 Anderson Center for Hair Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.3.4 Anderson Center for Hair Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.3.5 Anderson Center for Hair Recent Development13.4 Evolution Hair Loss Institute 13.4.1 Evolution Hair Loss Institute Company Details 13.4.2 Evolution Hair Loss Institute Business Overview and Its Total Revenue 13.4.3 Evolution Hair Loss Institute Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.4.4 Evolution Hair Loss Institute Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.4.5 Evolution Hair Loss Institute Recent Development13.5 Savola Aesthetic Dermatology Center 13.5.1 Savola Aesthetic Dermatology Center Company Details 13.5.2 Savola Aesthetic Dermatology Center Business Overview and Its Total Revenue 13.5.3 Savola Aesthetic Dermatology Center Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.5.4 Savola Aesthetic Dermatology Center Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.5.5 Savola Aesthetic Dermatology Center Recent Development13.6 Virginia Surgical Center 13.6.1 Virginia Surgical Center Company Details 13.6.2 Virginia Surgical Center Business Overview and Its Total Revenue 13.6.3 Virginia Surgical Center Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.6.4 Virginia Surgical Center Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.6.5 Virginia Surgical Center Recent Development13.7 Hair Transplant Institute of Miami 13.7.1 Hair Transplant Institute of Miami Company Details 13.7.2 Hair Transplant Institute of Miami Business Overview and Its Total Revenue 13.7.3 Hair Transplant Institute of Miami Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.7.4 Hair Transplant Institute of Miami Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.7.5 Hair Transplant Institute of Miami Recent Development13.8 Colorado Surgical Center & Hair Institute 13.8.1 Colorado Surgical Center & Hair Institute Company Details 13.8.2 Colorado Surgical Center & Hair Institute Business Overview and Its Total Revenue 13.8.3 Colorado Surgical Center & Hair Institute Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Introduction 13.8.4 Colorado Surgical Center & Hair Institute Revenue in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business (2015-2020) 13.8.5 Colorado Surgical Center & Hair Institute Recent Development 14Analysts Viewpoints/Conclusions 15Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

More:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market to Grow Significantly With Increasing Advancements in Technology, Says QYR - News...

Others

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Stem Cell Therapy market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=285194&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=285194&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Go here to see the original:
Stem Cell Therapy Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

In early 2020, it seemed like people with diabetes were disproportionately dying with COVID-19, but the data provided more questions than answers. What type of diabetes did people have? Were people dying because the condition itself put them at greater risk, or because those with it tend to be older and have other illnesses? And what should people with diabetes do to protect themselves?

Now, researchers are harnessing data from NHS England to address these questions and some of their findings are unexpected.

It is still unclear whether people with diabetes are more likely to catch the virus. We wont know if this is true until sustained, widespread testing is rolled out. But we do know that a disproportionate number of people with the condition have been hospitalised with COVID-19. In the UK, data spanning February to April shows people with diabetes made up approximately 25% of hospitalised cases; thats almost four times higher than the estimated rate of diabetes in the general population.

Once in hospital with COVID-19, data also shows that people with diabetes have worse outcomes than people without. The increase in risk is striking but isnt necessarily surprising people with diabetes are prone to worse outcomes from infections generally, as data from flu shows.

When it comes to COVID-19, early studies suggest people with diabetes are approximately twice as likely to be categorised as having severe disease and are more likely to be admitted to intensive care units. In England, one in four people who die in hospital with COVID-19 have diabetes.

Previous studies, however, didnt shed light on the details behind these headline statistics, and didnt break down data by diabetes type. We now have this information, and it shows a significant and surprising difference.

Compared to people without diabetes, people with type 1 diabetes are approximately 3.5 times as likely to die in hospital with COVID-19, while people with type 2 are approximately twice as likely. This came as a surprise to some, because, unlike type 1, type 2 diabetes is often accompanied by other diseases, typically comes on in older age, and can be associated with raised body weight. All of these factors are linked to worse outcomes from COVID-19.

There are a number of possible explanations as to why outcomes are worse in type 1 compared to type 2.

First, the length of time someone has had diabetes might impact their vulnerability to COVID-19. Unlike type 2, people are most often diagnosed with type 1 at a young age (I was diagnosed at ten). In people hospitalised with COVID-19, someone with type 1 has likely had diabetes for much longer than someone with type 2. The longer someone has diabetes, the more likely they are to have complications, which include damage to the heart and kidneys.

Second, in type 1, your immune system attacks the cells that make insulin and you eventually stop making insulin altogether. Insulin is the hormone that helps the body process sugar in the blood. Type 2 isnt a disease of the immune system. In type 2, your body makes insulin but is resistant to it. The immune systems of people with type 1 may be different from people with type 2, which could impact how people respond to infection.

Finally, data shows that higher blood sugar levels increase the risk of COVID-19. We know that on average blood sugar levels are higher in people with type 1 than with type 2 diabetes, because of the different nature of the diseases. Blood sugar levels can be even harder to manage when fighting infections.

But these are all just theories. We need more research before we know for sure how the type of diabetes impacts COVID-19 outcomes.

To illustrate this, Im going to use myself as an example and do some crude calculations. Im 36 and have type 1 diabetes. Most people with COVID-19 arent hospitalised. However, if hospitalised with COVID-19, the average 36-year-old has a 0.3% chance of dying. Because I have type 1 diabetes, my chances of dying are 3.5 times higher. That means my current chances of dying with COVID-19 once hospitalised are around 1%.

However, if the average 80-year-old is hospitalised with COVID-19, they have a 15% chance of dying. So, though diabetes does increase my risk, my age still remains the most important factor, by far, in determining my chances of dying with COVID-19. My risk at 80 would still be higher than someone of that age without diabetes, so both would need to be taken into account.

It is really important to note that these figures are not someones overall risk of dying from COVID-19, they are the risk of dying if they contract COVID-19 and if the infection is then severe enough to warrant hospitalisation.

The advice to people with diabetes is to practice social distancing and handwashing like the rest of the population, to maintain a healthy lifestyle, and to try to keep blood sugars in an ideal range where possible.

But aiming for tighter blood sugar control can feel daunting. Now might be a particularly difficult time for people to manage diabetes, with disruptions in care, routines, activity, mental wellbeing and diet known to create challenges. Certain groups will face more challenges than others; both COVID-19 and diabetes disproportionately affect people from non-white ethnic groups and people from less advantaged backgrounds.

Support is available from healthcare providers and from organisations like Diabetes UK. Now more than ever, governments and healthcare systems need to ensure all people with diabetes get the support they need.

View original post here:
Coronavirus and diabetes: the different risks for people with type 1 and type 2 - The Conversation UK

Loss of a pregnancy may increase a womans risk of developing Type 2 diabetes, Danish researchers report.

Their study, in Diabetologia, included 24,774 women who developed diabetes after pregnancy and 247,740 controls who did not.

Compared with women who had been pregnant without losing a baby, those who lost one were at an 18 percent increased risk for diabetes, those who lost two were at a 38 percent higher risk and those who lost three or more had a 71 percent higher risk. The study adjusted for obesity and gestational diabetes, which are known to be associated with the development of Type 2 diabetes.

The reason for the association remains unknown. It may be that the same genetic background increases the risk for both pregnancy loss and diabetes, or that pre-diabetes present before the diagnosis of diabetes could lead to both. In any case, the authors stress that the observational finding does not prove cause and effect.

The lead author, Dr. Pia Egerup, a researcher at the Recurrent Pregnancy Loss Unit of the Rigshospitalet and Hvidovre Hospital in Copenhagen, said that the most important clinical implication is that pregnancy loss is a risk factor for diabetes.

Pregnancy loss is not only due to fetal disease, she said. A large proportion are healthy fetuses lost because of maternal conditions. As clinicians, we want to optimize pregnancy success and minimize the risk for future diabetes.

See the original post here:
Pregnancy Loss Tied to Increased Risk of Type 2 Diabetes - The New York Times

By

MATTHEW PERRONE AP Health Writer

May 29, 2020, 7:30 PM

2 min read

2 min read

WASHINGTON -- U.S. health regulators are telling five drugmakers to recall their versions of a widely used diabetes medication after laboratory tests found elevated levels of a contaminant linked to cancer.

The Food and Drug Administration said late Thursday that several batches of the drug metformin tested positive for unsafe levels of a chemical called N-Nitrosodimethylamine. The agency has stepped up testing after the chemical was found in dozens of shipments of heartburn drugs last year, triggering recalls of Zantac and other popular over-the-counter and prescription medications.

Metformin tablets are a staple of diabetes care, reducing excess sugar in the blood. People with Type 2 diabetes use metformin alone or with other drugs to help control their blood sugar levels. More than 34 million people in the U.S. have this disease.

Patients should continue taking metformin drugs until their doctor can prescribe a replacement, the FDA said in a statement, noting the risks of discontinuing. Regulators are still assessing whether the recalls will lead to shortages of metformin, but noted that a number of other companies make generic versions of the drugs that don't appear to be affected by the issue.

Drugmaker Apotex Corp. recalled its extended-release metformin distributed in the U.S. earlier this week after the FDA found contamination in one lot. Apotex said in a statement it recalled all supplies of the drug out of an abundance of caution. The company said it stopped selling the drug in the U.S. in February 2019 and that little remains on the market.

The FDA announcement did not name the four other drugmakers who have been requested to recall their products.

The agency noted that no contamination problems have been found in immediate-release metformin.

The FDA is responsible for ensuring that medicines for the U.S. market are made in safe, sanitary conditions that meet federal quality standards. But government inspectors have repeatedly criticized the agency for falling short in reviewing overseas manufacturing plants as the pharmaceutical supply chain has increasingly spread to Asia.

In March, the FDA suspended nearly all U.S. and foreign inspections due to safety concerns and travel restrictions caused by the coronavirus outbreak.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

Go here to read the rest:
FDA finds contamination in several brands of diabetes drug - ABC News

The time of puberty onset may help predict the risk of diabetes in men. The earlier boys experienced the onset of puberty, the higher their risk of developing type 2 diabetes as adults, reveals a new study, published in the journal Diabetologia in March 2020. Also Read - 40% of diabetic patients initially decline insulin therapy: All you need to know about this disease

The findings may help establish guidelines for prevention and testing for diabetes in men. It may also lead to new interventions against the chronic condition that affects the way your body metabolizes sugar (glucose). Also Read - Trigger finger and other surprising signs of type 2 diabetes you might be ignoring so far

For the study, the researchers the University of Gothenburg in Sweden assessed more than 30,600 Swedish men born between 1945 and 1961. They found that those who had their pubertal growth spurt at age 9.3 to 13.4 years had a twofold risk of developing early type 2 diabetes than those who had the growth spurt at the age of 14.8 to 17.9 years. Also Read - Suffering from type 2 diabetes? Watch what youre eating for your breakfast

For each year earlier that the pubertal growth spurt occurred, the risk of developing early diabetes went up by 28 per cent, while the risk of late diabetes increased by 13 per cent. Men who had early pubertal growth spurt were also found to be more likely to require insulin treatment if they went on to develop type 2 diabetes.

While the researchers are not very clear about the underlying mechanisms of this association, they believe that that early puberty may lead to build-up of excess fat in the abdominal area. This may in turn leads to high blood pressure, diabetes, and abnormal lipid levels, which are all risk factors for cardiac and metabolic disease.

Earlier studies have already found an association between a high adult BMI and a higher risk for type 2 diabetes. It is also known that boys with a high BMI in childhood or during puberty have a greater diabetes risk. Some studies have also linked earlier onset of puberty in girls, as defined by the beginning of menstruation, to a higher risk of diabetes.

Jenny Kindblom, co-author of the new study, noted that their findings suggest that early puberty could be a novel independent risk factor for type 2 diabetes in men. She believes that a continuous monitoring of height and weight development during both childhood and adolescence may help identify individuals with increased risk of type of diabetes.

Type 2 diabetes occurs when your body either resists the effects of insulin or doesnt produce enough insulin to maintain normal glucose levels. Insulin is a hormone secreted by the pancreas and it helps regulate the movement of sugar into your cells.

Signs and symptoms of type 2 diabetes often develop gradually over time. They can be so mild that you can have type 2 diabetes for years and not know about it. Here are some symptoms to watch out for:

Unfortunately, theres no cure for type 2 diabetes. However, you can control the disease by maintaining a healthy weight, eating well and exercising. Some people may need diabetes medications or insulin therapy to manage their blood sugar levels.

Published : May 31, 2020 7:15 pm | Updated:June 1, 2020 8:13 am

Read the rest here:
Men who had early puberty at higher risk of developing type 2 diabetes - TheHealthSite

Insulet(NASDAQ:PODD)earlier this month reported first-quarter 2020 results. The tubeless insulin pump specialist's results were quite strong, especially in light of the COVID-19 pandemic.

In 2020, shares of thehealthcare companyare up 10.2% through the end of May, outpacing the broader market, which is down about 5% because of the pandemic. Insulet stock remains a huge winner over the intermediate and long terms. Over the past five years, it's gained 567%, versus the broader market's 60% return.

Here's how the quarter worked out for Insulet and its investors.

Image source: Insulet.

Metric

Q1 2020

Q1 2019

Change

Revenue

Operating income

Net income

Earnings per share (EPS)

Data source: Insulet.

Revenue easily beat Insulet's guidance of growth of 17% to 20% year over year. For context, in the prior quarter, revenue grew 27% year over year.

The year-over-year decline on the bottom line was driven by an increase in interest expense.

Here's what CEO Shacey Petrovic had to say in the press release:

Insulet entered 2020 with positive momentum, making progress toward our strategic objectives and achieving strong revenue growth ahead of expectations. The efficiency and redundancy we have built in our supply chain and manufacturing operations enabled us to meet customer demand without interruption during this challenging time. We believe that our proven, durable annuity business model will continue to generate double-digit revenue growth in 2020. We remain confident we have the right strategic framework to effectively advance our mission, drive sustainable long-term growth throughout our global business, and to continue to create shareholder value.

On the earnings call, CFO McMillan quantified what Petrovic termed the company's "annuity business model," or what others might consider a razor-and-blade model: "Historically, new Omnipod starts within any given quarter contributed approximately 10% of revenue." In other words, the vast majority of quarterly revenue has come from existing Omnipod users purchasing new pods.

The Omnipod has no upfront cost, as it's a pay-as-you-go product, which means sales should hold up better in a recessionary environment relative to products that have considerable upfront costs.

Insulet's Q1 results were quite robust despite headwinds presented by the pandemic.

Unlike many companies, it didn't lower or pull its full-year 2020 guidance. Management reaffirmed its previously issued 2020 outlook of revenue growth of 14% to 18% over 2019. However, it did say that it now expects revenue to come in at the low end of this outlook. The company doesn't issue earnings guidance.

Due to the pandemic, Insulet's U.S. launch of its Omnipod Horizon automated insulin delivery system, which uses aDexCom(NASDAQ:DXCM) continuous glucose monitor (CGM) to dose insulin, has been pushed back. Management now expects this launch to occur in the first half of 2021, rather than in late 2020, Petrovic said on the earnings call.

Go here to read the rest:
This Diabetes Company's Q1 Earnings Reflect the Resiliency of Its Business Model - The Motley Fool